{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:42:17Z","timestamp":1791423737094,"version":"4.3.3"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ando.2026.102511","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T07:45:28Z","timestamp":1774338328000},"page":"102511","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Genome architecture in endocrine diseases: X-linked acrogigantism (X-LAG) syndrome"],"prefix":"10.1016","volume":"87","author":[{"given":"Adrian F.","family":"Daly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Beckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"P\u00e9trossians","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2026.102511_bib0210","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","article-title":"Acromegaly: pathogenesis, diagnosis, and management","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ando.2026.102511_bib0215","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ecl.2020.04.002","article-title":"The epidemiology of pituitary adenomas","volume":"49","author":"Daly","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ando.2026.102511_bib0220","doi-asserted-by":"crossref","first-page":"e937","DOI":"10.1210\/clinem\/dgz096","article-title":"A consensus on the diagnosis and treatment of acromegaly comorbidities: an update","volume":"105","author":"Giustina","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2026.102511_bib0225","series-title":"The Pituitary","article-title":"Genetics of Pituitary Adenoma Syndromes","author":"Daly","year":"2022"},{"key":"10.1016\/j.ando.2026.102511_bib0230","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41574-018-0114-1","article-title":"The causes and consequences of pituitary gigantism","volume":"14","author":"Beckers","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ando.2026.102511_bib0235","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1530\/ERC-15-0320","article-title":"Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients","volume":"22","author":"Rostomyan","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2026.102511_bib0240","doi-asserted-by":"crossref","first-page":"E373","DOI":"10.1210\/jc.2009-2556","article-title":"Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an International Collaborative Study","volume":"95","author":"Daly","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2026.102511_bib0245","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1210\/er.2012-1013","article-title":"Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene","volume":"34","author":"Beckers","year":"2013","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2026.102511_bib0250","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa1408028","article-title":"Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation","volume":"371","author":"Trivellin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2026.102511_bib0255","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1530\/ERC-15-0038","article-title":"X-linked acrogigantism syndrome: clinical profile and therapeutic responses","volume":"22","author":"Beckers","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2026.102511_bib0260","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1008020","article-title":"AIP mutation in pituitary adenomas in the 18th century and today","volume":"364","author":"Chahal","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2026.102511_bib0265","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40478-016-0328-1","article-title":"Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study","volume":"4","author":"Iacovazzo","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.ando.2026.102511_bib0270","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1038\/s41467-020-18500-x","article-title":"GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq\/11","volume":"11","author":"Abboud","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ando.2026.102511_bib0275","doi-asserted-by":"crossref","first-page":"111091","DOI":"10.1016\/j.mce.2020.111091","article-title":"The X-linked acrogigantism-associated gene gpr101 is a regulator of early embryonic development and growth in zebrafish","volume":"520","author":"Trivellin","year":"2021","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ando.2026.102511_bib0280","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/JME-16-0045","article-title":"Characterization of GPR101 transcript structure and expression patterns","volume":"57","author":"Trivellin","year":"2016","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.ando.2026.102511_bib0285","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41589-023-01456-6","article-title":"Structure of GPR101-Gs enables identification of ligands with rejuvenating potential","volume":"20","author":"Yang","year":"2023","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.ando.2026.102511_bib0290","first-page":"1","article-title":"GPR101: modeling a constitutively active receptor linked to X-linked acrogigantism","volume":"127","author":"Costanzi","year":"2023","journal-title":"J Mol Graph Model"},{"key":"10.1016\/j.ando.2026.102511_bib0295","doi-asserted-by":"crossref","first-page":"116013","DOI":"10.1016\/j.bcp.2023.116013","article-title":"Basal interaction of the orphan receptor GPR101 with arrestins leads to constitutive internalization","volume":"220","author":"Abboud","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ando.2026.102511_bib0300","doi-asserted-by":"crossref","first-page":"1345363","DOI":"10.3389\/fendo.2024.1345363","article-title":"Case report: management of pediatric gigantism caused by the TADopathy, X-linked acrogigantism","volume":"15","author":"Caruso","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ando.2026.102511_bib0305","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1530\/ERC-16-0082","article-title":"Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects","volume":"23","author":"Daly","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2026.102511_bib0310","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2015-4366","article-title":"Somatic GPR101 duplication causing X-linked acrogigantism (XLAG)-diagnosis and management","volume":"101","author":"Rodd","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2026.102511_bib0315","doi-asserted-by":"crossref","DOI":"10.1210\/endrev\/bnae014","article-title":"The genetic pathophysiology and clinical management of the TADopathy, X-linked acrogigantism","volume":"45","author":"Daly","year":"2024","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2026.102511_bib0320","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1210\/jc.2019-00817","article-title":"Familial X-linked acrogigantism: postnatal outcomes and tumor pathology in a prenatally diagnosed infant and his mother","volume":"104","author":"Wise-Oringer","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2026.102511_bib0325","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1530\/ERC-15-0478","article-title":"GHRH excess and blockade in X-LAG syndrome","volume":"23","author":"Daly","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ando.2026.102511_bib0330","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41574-025-01148-2","article-title":"Consensus on acromegaly therapeutic outcomes: an update","volume":"21","author":"Melmed","year":"2025","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ando.2026.102511_bib0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2026.102511_bib0340","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12020-015-0804-6","article-title":"Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome","volume":"51","author":"Naves","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.ando.2026.102511_bib0345","article-title":"Effective long-term pediatric pegvisomant monotherapy to final height in X-linked acrogigantism","volume":"1","author":"Burren","year":"2023","journal-title":"JCEM Case Rep"},{"key":"10.1016\/j.ando.2026.102511_bib0350","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nature19800","article-title":"Formation of new chromatin domains determines pathogenicity of genomic duplications","volume":"538","author":"Franke","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ando.2026.102511_bib0355","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.tig.2016.01.003","article-title":"Breaking TADs: how alterations of chromatin domains result in disease","volume":"32","author":"Lupi\u00e1\u00f1ez","year":"2016","journal-title":"Trends Genet"},{"key":"10.1016\/j.ando.2026.102511_bib0360","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature11082","article-title":"Topological domains in mammalian genomes identified by analysis of chromatin interactions","volume":"485","author":"Dixon","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ando.2026.102511_bib0365","doi-asserted-by":"crossref","first-page":"e02557","DOI":"10.7554\/eLife.02557","article-title":"Temporal dynamics and developmental memory of 3D chromatin architecture at Hox gene loci","volume":"3","author":"Noordermeer","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.ando.2026.102511_bib0370","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.cell.2013.04.053","article-title":"Architectural protein subclasses shape 3D organization of genomes during lineage commitment","volume":"153","author":"Phillips-Cremins","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ando.2026.102511_bib0375","doi-asserted-by":"crossref","first-page":"102622","DOI":"10.1016\/j.sbi.2023.102622","article-title":"TADs: dynamic structures to create stable regulatory functions","volume":"81","author":"da Costa-Nunes","year":"2023","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.ando.2026.102511_bib0380","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.cell.2015.04.004","article-title":"Disruptions of topological chromatin domains cause pathogenic rewiring of gene-enhancer interactions","volume":"161","author":"Lupi\u00e1\u00f1ez","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ando.2026.102511_bib0385","doi-asserted-by":"crossref","first-page":"e2300010","DOI":"10.1002\/bies.202300010","article-title":"Disruption of regulatory domains and novel transcripts as disease-causing mechanisms","volume":"45","author":"Allou","year":"2023","journal-title":"Bioessays"},{"key":"10.1016\/j.ando.2026.102511_bib0390","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ajhg.2022.02.002","article-title":"Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism","volume":"109","author":"Franke","year":"2022","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ando.2026.102511_bib0400","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41525-025-00548-7","article-title":"Distinguishing benign from pathogenic duplications involving GPR101 and VGLL1-adjacent enhancers in the clinical setting with the bioinformatic tool POSTRE","volume":"11","author":"Trivellin","year":"2026","journal-title":"NPJ Genom Med"},{"key":"10.1016\/j.ando.2026.102511_bib0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-024-01378-5","article-title":"Chromatin conformation capture in the clinic: 4C-seq\/HiC distinguishes pathogenic from neutral duplications at the GPR101 locus","volume":"16","author":"Daly","year":"2024","journal-title":"Genome Med"},{"key":"10.1016\/j.ando.2026.102511_bib0405","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11102-025-01559-4","article-title":"Non-penetrant Xq26.3 duplication involving the invariant TAD border: clinical evidence for the VGLL1 region as the GPR101 pituitary enhancer of X-linked acrogigantism","volume":"28","author":"Hilditch","year":"2025","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2026.102511_bib0410","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1093\/nar\/gkad225","article-title":"POSTRE: a tool to predict the pathological effects of human structural variants","volume":"51","author":"S\u00e1nchez-Gaya","year":"2023","journal-title":"Nucleic Acids Res"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426626000326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426626000326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:42:40Z","timestamp":1780105360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426626000326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0003426626000326"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2026.102511","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genome architecture in endocrine diseases: X-linked acrogigantism (X-LAG) syndrome","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2026.102511","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102511"}}